Relapsing Forms of Multiple Sclerosis | Unmet Need | US/EU | 2018

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings in efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved alternatives. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing forms of MS and the current level of unmet need in this area. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities, with a subfocus on next-generation oral DMTs in our conjoint-based Target Product Profile simulator.

QUESTIONS ANSWERED

• What are the treatment drivers and goals for relapsing forms of MS?
• What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for relapsing forms of MS?
• What are the prevailing areas of unmet need and opportunity in relapsing forms of MS?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new oral drug for relapsing forms of MS?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in December 2017.

Key companies: Biogen, Novartis, Teva, Roche, Merck, Sanofi/Genzyme.

Key drugs: Gilenya, Aubagio, Tecfidera, Copaxone, Avonex, Tysabri, Ocrevus, Mavenclad.

Key metrics included:

• Stated versus derived analysis of U.S. and European physician prescribing behavior.
• Conjoint analysis of oral DMTs with U.S. and European physicians, includes market simulator.
• Assessment of current drug performance against treatment drivers and goals.
• Physician perceptions of unmet need in disease covered and related diseases.
• Analysis of remaining drug development opportunities.